Pfizer to Acquire Therachon for the Expansion of its Rare Disease Portfolio


  • Pfizer acquires Therachon, in all stock transaction for $810M. Therachon to receive $340M upfront with additional payment on milestones of development and commercialization of its  TA-46 candidate targeted for achondroplasia
  • Additionally, Therachon to spin-off its apraglutide development program into an independent firm, prior closure of the transaction. Pfizer Ventures to hold an equity stake in the new firm
  • TA-46 is a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy has completed its P-I for achondroplasia and has received EMA’s and FDA’s ODD. Apraglutide is a qw GLP-2 analog P-II candidate targeted for short bowel syndrome

Click here to read full press release/ article | Ref: Pfizer | Image: Twitter